Product Description
contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01865487)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aeras
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Latent Tuberculosis
Phase 1: Latent Tuberculosis|Tuberculosis